A Comprehensive Review of Bioinformatics Tools for Genomic Biomarker Discovery Driving Precision Oncology
- PMID: 39202397
- PMCID: PMC11353282
- DOI: 10.3390/genes15081036
A Comprehensive Review of Bioinformatics Tools for Genomic Biomarker Discovery Driving Precision Oncology
Abstract
The rapid advancement of high-throughput technologies, particularly next-generation sequencing (NGS), has revolutionized cancer research by enabling the investigation of genetic variations such as SNPs, copy number variations, gene expression, and protein levels. These technologies have elevated the significance of precision oncology, creating a demand for biomarker identification and validation. This review explores the complex interplay of oncology, cancer biology, and bioinformatics tools, highlighting the challenges in statistical learning, experimental validation, data processing, and quality control that underpin this transformative field. This review outlines the methodologies and applications of bioinformatics tools in cancer genomics research, encompassing tools for data structuring, pathway analysis, network analysis, tools for analyzing biomarker signatures, somatic variant interpretation, genomic data analysis, and visualization tools. Open-source tools and repositories like The Cancer Genome Atlas (TCGA), Genomic Data Commons (GDC), cBioPortal, UCSC Genome Browser, Array Express, and Gene Expression Omnibus (GEO) have emerged to streamline cancer omics data analysis. Bioinformatics has significantly impacted cancer research, uncovering novel biomarkers, driver mutations, oncogenic pathways, and therapeutic targets. Integrating multi-omics data, network analysis, and advanced ML will be pivotal in future biomarker discovery and patient prognosis prediction.
Keywords: RNA-Seq; bioinformatics; biomarker discovery; oncology; predictive algorithms.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Zamora Atenza C., Anguera G., Riudavets Melià M., Alserawan De Lamo L., Sullivan I., Barba Joaquin A., Serra Lopez J., Ortiz M.A., Mulet M., Vidal S., et al. The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents. Cancer Immunol. Immunother. 2022;71:1823–1835. doi: 10.1007/s00262-021-03107-y. - DOI - PMC - PubMed
-
- Mullis K.B., Faloona F.A. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzym. 1987;155:335–350. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
